Disease | gastrointestinal stromal tumor |
Phenotype | C0023470|myelogenous leukemia |
Sentences | 1 |
PubMedID- 24348666 | It was initially proposed that the t790m mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance, similar to the corresponding gatekeeper mutations in bcr-abl (t315i) and kit (t670i) that confer resistance to imatinib (gleevec) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors. |
Page: 1